A Phase 4 interventional study of Platelet Rich Plasma in Osteoarthritis and Inflammatory Arthritis, sponsored by Exactech. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2022-09-01.
Sponsored by Exactech · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.
Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 4, and was the 1st registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:
Goed Medisch Centrum · Sites in Netherlands
Ages 18+
University of Utah · Sites in United States
Ages 18+ · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–100
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80
VivaTech International, Inc. · Sites in United States
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6 · Phase 4 7
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 70 across the 28 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 28 have an industry lead sponsor. The 10 most frequent:
Exactech is the lead sponsor of 17 studies on the registry; 9 are open to participants now.
Exactech has 4 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
2 of the studies testing platelet rich plasma in Osteoarthritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491302Goed Medisch CentrumThumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection | 2027-05 |
| NCT03734900National Taiwan University HospitalComparison of Effectiveness Between PL and PRP on Knee Osteoarthritis: a Prospective,Randomized,Placebo-controlled Trial | 2027-05-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing platelet rich plasma in Osteoarthritis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical study to evaluate the effect of platelet rich plasma (PRP), a derivative of a patient's whole blood, on short-term patient outcomes following total knee replacement (TKR).
The purpose of this clinical study is to evaluate the effect of platelet rich plasma (PRP), a derivative of a patient's whole blood, on short-term patient outcomes following total knee replacement (TKR). The hypothesis is that change in short-term hemoglobin (Hgb) levels is less dramatic in patients who undergo TKR with the addition of PRP when compared to patients who undergo TKR without PRP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Total knee replacement with PRP
Biological: Platelet Rich Plasma
Total knee replacement without PRP
Addition of PRP to total knee replacement procedure
Also known as: Accelerate PRP
Hemoglobin level
Hemoglobin level analysis
Time frame: Change in hemoglobin (Hgb) level (preop compared to postop day 2)
The record gives a start of Dec 2008, a primary completion of Jun 2011 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma
Exactech